Mohammed Auwal Ibrahim1, James Dama Habila2, Neil Anthony Koorbanally2, Md Shahidul Islam3. 1. School of Life Sciences, University of KwaZulu-Natal (Westville Campus), Durban 4000 South Africa; Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria. 2. School of Chemistry, University of KwaZulu-Natal (Westville Campus), Durban 4000 South Africa. 3. School of Life Sciences, University of KwaZulu-Natal (Westville Campus), Durban 4000 South Africa. Electronic address: islamd@ukzn.ac.za.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Ethnopharmacological surveys have reported that Parkia biglobosa (Jacq.) G. Don (Leguminosae) is among the plants commonly used in the traditional management of diabetes mellitus in Nigeria and Togo. AIM OF THE STUDY: This study investigated the anti-diabetic activity of the butanol fraction of P. biglobosa leaves (PBBF) in a type 2 diabetes (T2D) model of rats and a possible bioactive compound in the fraction. MATERIALS AND METHODS: T2D was induced by feeding rats with a 10% fructose solution ad libitum for two weeks followed by an intraperitoneal injection of 40mg/kg body weight streptozotocin and the animals were orally treated with 150 and 300mg/kg BW of the PBBF for five days in a week. Another group of rats was non-diabetic but similarly administered with 300mg/kg BW of the PBBF. Food and fluid intakes, body weight changes and blood glucose levels were monitored during the experiment while other relevant diabetes-associated parameters were measured at the end of the experiment. RESULTS: The PBBF treatments significantly (P<0.05) decreased the blood glucose levels and improved the glucose tolerance ability compared to untreated diabetic rats. Furthermore, the treatments were found to improve pancreatic β cell function (HOMA-β), stimulate insulin secretions, decrease insulin resistance (HOMA-IR), restore liver glycogen, ameliorate serum dyslipidaemia and prevent hepatic and renal damages compared to untreated diabetic rats. Phytochemical analysis of the fraction led to the isolation of lupeol which inhibited α-glucosidase and α-amylase in non-competitive and uncompetitive inhibition patterns respectively. CONCLUSION: It was concluded that PBBF possessed remarkable anti-T2D activity which is mediated through modulation of β-cell function and stimulation of insulin secretion and the lower dose (150mg/kg BW) was found optimum for anti-T2D activity compared to the high dose (300mg/kg BW) in this study.
ETHNOPHARMACOLOGICAL RELEVANCE: Ethnopharmacological surveys have reported that Parkia biglobosa (Jacq.) G. Don (Leguminosae) is among the plants commonly used in the traditional management of diabetes mellitus in Nigeria and Togo. AIM OF THE STUDY: This study investigated the anti-diabetic activity of the butanol fraction of P. biglobosa leaves (PBBF) in a type 2 diabetes (T2D) model of rats and a possible bioactive compound in the fraction. MATERIALS AND METHODS: T2D was induced by feeding rats with a 10% fructose solution ad libitum for two weeks followed by an intraperitoneal injection of 40mg/kg body weight streptozotocin and the animals were orally treated with 150 and 300mg/kg BW of the PBBF for five days in a week. Another group of rats was non-diabetic but similarly administered with 300mg/kg BW of the PBBF. Food and fluid intakes, body weight changes and blood glucose levels were monitored during the experiment while other relevant diabetes-associated parameters were measured at the end of the experiment. RESULTS: The PBBF treatments significantly (P<0.05) decreased the blood glucose levels and improved the glucose tolerance ability compared to untreated diabeticrats. Furthermore, the treatments were found to improve pancreatic β cell function (HOMA-β), stimulate insulin secretions, decrease insulin resistance (HOMA-IR), restore liver glycogen, ameliorate serum dyslipidaemia and prevent hepatic and renal damages compared to untreated diabeticrats. Phytochemical analysis of the fraction led to the isolation of lupeol which inhibited α-glucosidase and α-amylase in non-competitive and uncompetitive inhibition patterns respectively. CONCLUSION: It was concluded that PBBF possessed remarkable anti-T2D activity which is mediated through modulation of β-cell function and stimulation of insulin secretion and the lower dose (150mg/kg BW) was found optimum for anti-T2D activity compared to the high dose (300mg/kg BW) in this study.
Authors: Shabnam Radbakhsh; Amir Abbas Momtazi-Borojeni; Ali Mahmoudi; Mohammad Reza Sarborji; Mahdi Hatamipour; Seyed Adel Moallem; Stephen L Atkin; Amirhossein Sahebkar Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Ahmed M Naglah; Moamen S Refat; Mohamed A Al-Omar; Mashooq A Bhat; Hamad M AlKahtani; Asma S Al-Wasidi Journal: Drug Des Devel Ther Date: 2019-04-30 Impact factor: 4.162